Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News

Table of Contents

What We're Reading

  • What We're Reading
    Literature Round-Up: Impactful Published Papers
    Cancer Immunol Res June 1 2018 6 (6) 629-629;

Cancer Immunology Miniature

  • Cancer Immunology Miniature
    Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event
    Mizuki Nishino, Lynette M. Sholl, Mark M. Awad, Hiroto Hatabu, Philippe Armand and F. Stephen Hodi
    Cancer Immunol Res June 1 2018 6 (6) 630-635; DOI:10.1158/2326-6066.CIR-17-0715

    Development of sarcoid-like granulomatosis of the lung after immune-checkpoint inhibition was observed in four patients with different tumor types. This manifestation had distinct clinical, imaging, and histological features, which characterized it as an immune-related adverse event.

Priority Brief

  • Priority Brief
    NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors
    Christa I. DeVette, Massimo Andreatta, Wilfried Bardet, Steven J. Cate, Vanessa I. Jurtz, Kenneth W. Jackson, Alana L. Welm, Morten Nielsen and William H. Hildebrand
    Cancer Immunol Res June 1 2018 6 (6) 636-644; DOI:10.1158/2326-6066.CIR-17-0298

    An improved peptide prediction tool for murine MHC class I presentation, NetH2pan, was created and cross-validated on MMTV-PyMT tumors. Its predictive powers were more accurate than other tools, enabling epitope discovery in the FVB and other mouse strains.

Research Articles

  • Research Articles
    IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer
    Ran You, Francesco J. DeMayo, Jian Liu, Sung-Nam Cho, Bryan M. Burt, Chad J. Creighton, Roberto F. Casal, Donald R. Lazarus, Wen Lu, Hui-Ying Tung, Xiaoyi Yuan, Andrea Hill-McAlester, Myunghoo Kim, Sarah Perusich, Loraine Cornwell, Daniel Rosen, Li-zhen Song, Silke Paust, Gretchen Diehl, David Corry and Farrah Kheradmand
    Cancer Immunol Res June 1 2018 6 (6) 645-657; DOI:10.1158/2326-6066.CIR-17-0554

    The pro-inflammatory cytokine IL17A has antitumor effects in certain subtypes of non–small cell lung cancer. Mice whose tumors were infiltrated with IL17A-expressing T cells were associated with increased lung cancer latency and had fewer metastasis.

  • Research Articles
    Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
    Luciano Castiello, Paola Sestili, Giovanna Schiavoni, Rosanna Dattilo, Domenica M. Monque, Fiorella Ciaffoni, Manuela Iezzi, Alessia Lamolinara, Antonella Sistigu, Federica Moschella, Anna Maria Pacca, Daniele Macchia, Maria Ferrantini, Ann Zeuner, Mauro Biffoni, Enrico Proietti, Filippo Belardelli and Eleonora Aricò
    Cancer Immunol Res June 1 2018 6 (6) 658-670; DOI:10.1158/2326-6066.CIR-17-0675

    Type I interferon (IFN-I) inhibits tumor growth and activates antitumor responses. HER2-driven tumors in mice lacking IFN-I receptor were more aggressive, more vascularized, and were enriched in stem cells, suggesting that IFN-I exerts key control over tumor progression.

  • Research Articles | AuthorChoice
    Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
    Zhiwei Hu, Rulong Shen, Amanda Campbell, Elizabeth McMichael, Lianbo Yu, Bhuvaneswari Ramaswamy, Cheryl A. London, Tian Xu and William E. Carson III
    Cancer Immunol Res June 1 2018 6 (6) 671-684; DOI:10.1158/2326-6066.CIR-17-0343

    Expression of tissue factor (TF) on the cancer cells and tumor neovasculature of triple-negative breast cancer provides a target for immunotherapy. An improved TF-targeting second-generation immunoconjugate (called L-ICON1) was tested for immunotherapy of this malignancy in preclinical mouse models.

  • Research Articles | AuthorChoice
    IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors
    Hyungseok Seo, Byung-Seok Kim, Eun-Ah Bae, Byung Soh Min, Yoon Dae Han, Sang Joon Shin and Chang-Yuil Kang
    Cancer Immunol Res June 1 2018 6 (6) 685-695; DOI:10.1158/2326-6066.CIR-17-0708

    Combination rIL21 and anti–PD-1/anti–Tim-3 additively enhanced NK cell responses in mice bearing MHCclass I–deficient tumors. This combination facilitated NK effector functions in cancer patients, highlighting its therapeutic potential for patients with MHC class I–deficient tumors.

  • Research Articles | AuthorChoice
    Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
    Chih-Hang Anthony Tang, Shiun Chang, Ayumi Hashimoto, Yi-Ju Chen, Chang Won Kang, Anthony R. Mato, Juan R. Del Valle, Dmitry I. Gabrilovich and Chih-Chi Andrew Hu
    Cancer Immunol Res June 1 2018 6 (6) 696-710; DOI:10.1158/2326-6066.CIR-17-0582

    In a mouse model of chronic lymphocytic leukemia, production of secretory IgM led to more MDSCs, fewer T cells, and shorter survival times for the mice. Thus, secretory IgM may aggravate the progression of this cancer.

  • Research Articles | AuthorChoice
    TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
    Ilaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli, Salvatore Caponnetto, Fabio Calabrò, Alain Gelibter, Aurelia Rughetti, Ilary Ruscito, Hassan Rahimi, Ernesto Rossi, Giovanni Schinzari, Paolo Marchetti and Marianna Nuti
    Cancer Immunol Res June 1 2018 6 (6) 711-722; DOI:10.1158/2326-6066.CIR-17-0594

    Pazopanib, a kinase inhibitor that targets angiogenesis, primed dendritic cells from patients with metastatic renal cell carcinoma and healthy donors. The resultant immune response indicates that this could be exploited to improve outcomes for patients undergoing combination immunotherapy.

  • Research Articles
    PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF
    Girija Goyal, Karrie Wong, Christopher J. Nirschl, Nicholas Souders, Donna Neuberg, Niroshana Anandasabapathy and Glenn Dranoff
    Cancer Immunol Res June 1 2018 6 (6) 723-732; DOI:10.1158/2326-6066.CIR-17-0612

    PPARγ deficiency in myeloid cells reduced the efficacy of GVAX cancer vaccines, altered DC gene expression and function, and decreased the ratio of vaccine-induced CD8+ T cells to Tregs. Correspondingly, PPARγ agonists improved the efficacy of cancer immunotherapy.

  • Research Articles
    Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs
    Kotaro Miyao, Seitaro Terakura, Shingo Okuno, Jakrawadee Julamanee, Keisuke Watanabe, Hiroshi Hamana, Hiroyuki Kishi, Reona Sakemura, Daisuke Koyama, Tatsunori Goto, Tetsuya Nishida, Makoto Murata and Hitoshi Kiyoi
    Cancer Immunol Res June 1 2018 6 (6) 733-744; DOI:10.1158/2326-6066.CIR-17-0538

    It may be safer to improve adoptive T-cell therapy through increased signaling rather than increased antigen affinity of the TCRs. Modifying intracellular signaling enhanced the proliferation and persistence of CTLs while improving antitumor efficacy.

  • Research Articles
    Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML
    Hiroshi Ureshino, Takero Shindo, Hiroto Kojima, Yasushi Kusunoki, Yuki Miyazaki, Hidenori Tanaka, Hiroh Saji, Atsushi Kawaguchi and Shinya Kimura
    Cancer Immunol Res June 1 2018 6 (6) 745-754; DOI:10.1158/2326-6066.CIR-17-0462

    In CML patients treated with tyrosine kinase inhibitors, KIR alleles were associated with patient outcome. The combination of alleles at KIR3DL1 and HLA-B loci were found to predict the therapeutic effects of tyrosine kinase inhibitor therapy.

Back to top
PreviousNext
Cancer Immunology Research: 6 (6)
June 2018
Volume 6, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Cancer Immunology Miniature
  • Priority Brief
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Case Report: RNA CAR T Cells
  • PD-L1 in Triple-Negative Breast Cancer
  • Bevacizumab plus Ipilimumab
  • Vaccine-Induced Intratumoral Lymphoid Aggregates
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement